Latest news
Oak Hill Bio Announces Dosing of First Participant in BEACON Phase 3 Clinical Trial of Rugonersen in Angelman Syndrome - The Manila TimesThe Manila Times · Tue, 28 Jul 2026 12:18:36 GMTOak Hill takes SPAC track to Nasdaq with Roche asset in tow - BioSpaceBioSpace · Tue, 28 Jul 2026 07:00:00 GMTOak Hill Bio merges with RA Capital SPAC; InnoCare’s TYK2 drug hits in Phase 3 - Endpoints NewsEndpoints News · Tue, 28 Jul 2026 07:00:00 GMTOak Hill to get $175M cash infusion in merger with RA Capital-backed SPAC - FirstWord PHARMAFirstWord PHARMA · Tue, 28 Jul 2026 00:00:14 GMTWilson Sonsini Advises Oak Hill Bio on IP Matters in Proposed Business Combination with RACC - Wilson SonsiniWilson Sonsini · Mon, 27 Jul 2026 23:09:12 GMTRA Capital launches Oak Hill Bio onto the Nasdaq via SPAC - Fierce BiotechFierce Biotech · Mon, 27 Jul 2026 19:25:29 GMTCambridge biotech to go public via RA Capital-backed SPAC - The Business JournalsThe Business Journals · Mon, 27 Jul 2026 18:40:00 GMTRA Capital-backed Oak Hill to go public in USD 175m SPAC deal - AllSciAllSci · Mon, 27 Jul 2026 14:19:47 GMT